Cauliflower Mushroom
fungus SparassidaceaeSparassis crispa
Also known as: Hanabiratake (Japan), Cauliflower Fungus, Sparassis latifolia (East Asian species)
clinical_notes Clinical Summary
Sparassis crispa (Cauliflower Mushroom) is distinguished by the highest beta-glucan content of any known mushroom (>40% dry weight as SCG, a 6-branched 1,3-beta-D-glucan), conferring potent immunomodulatory, antitumor, hematopoietic, antidiabetic, and anti-angiogenic activities.
SCG activates innate immunity via TLR4 and Dectin-1 receptors, suppresses tumor growth and metastasis in mouse models, accelerates wound healing in diabetic rats, and has been used in adjunctive cancer immunotherapy in Japan.
Meta-analysis of 33 RCTs (preclinical) supports significant antitumor and anti-inflammatory effects.
Pregnancy Safety
No reproductive safety data for supplemental doses. Culinary use likely safe. Medicinal extract doses should be avoided in pregnancy; rated B2.
Lactation Safety
No lactation data. Culinary quantities considered safe; medicinal extracts not recommended.
warning Contraindications
- Immunosuppressant therapy (caution)Theoretical
- Autoimmune disease (caution)Theoretical
vital_signs Clinical Profile
Primary Indications
- check_circle Immune support and adjunctive cancer therapy
- check_circle Type 2 diabetes and glycaemic control
- check_circle Hypertension
- check_circle Wound healing in diabetic patients
- check_circle Hematopoietic support after chemotherapy
- check_circle Anti-inflammatory conditions
- check_circle Antifungal and antibacterial infections
- check_circle Antioxidant protection
Therapeutic Actions
System Affinities
- check_circle immune system
- check_circle cardiovascular
- check_circle metabolic
- check_circle skin
- check_circle musculoskeletal
labs Active Constituents
Sparassis crispa beta-glucan / SCG
Sparassol
Ergosterol
Ergosterol peroxides
Benzoate derivatives
Polyphenols and flavonoids
Ceramides
Vitamins B, D2
Minerals
psychiatry Mycology
Large cauliflower-like mass of densely branched, flat wavy frilly lobes. Cream-white to pale yellow. 15–50 cm across, up to 5 kg. Single thick central base. Flesh firm, brittle, mild nutty aroma.
Base of conifer stumps and roots (especially pine, fir, spruce); brown-rot fungus attacking heartwood
Temperate conifer forests of North Temperate Zone — Japan, Korea, China, Europe, North America. Fruiting late summer to autumn. Cultivated on coniferous sawdust substrate.
fruiting body
White to pale cream
Commercially cultivated on coniferous sawdust substrate in Japan, Korea, and China since the 2000s. Fruiting body contains the highest beta-glucan concentration of any known mushroom (>40% of dry weight). Mycelium has lower beta-glucan content than fruiting body. Fruiting body always preferred for clinical applications.
Distinctive cauliflower morphology makes misidentification rare. May be confused with Sparassis latifolia (East Asian species, similar medicinal properties) or Ramaria species (coral fungi — some Ramaria are toxic). Verify conifer substrate origin and cream-white frilly lobe structure.
history_edu Traditional Use
No TCM data available for this herb yet.
Traditional Uses Across Healing Systems
While many herbs lack controlled clinical trials, centuries of traditional practice across cultures provide valuable insight into their therapeutic applications.
Immune tonic, anti-cancer food, general health tonic
Called Hanabiratake. Cultivation became popular in Japan in the 2000s. Used in cancer immunotherapy support protocols in integrative oncology settings.
Health tonic and immune food
Used in traditional Chinese dietary medicine as an immune-supporting health tonic
Immune and metabolic support
Widely cultivated and consumed for immune and antidiabetic properties
Edible tonic from forest environments
Harvested as wild edible health food in Himalayan regions
spa Parts Used
fruiting body
- Immune modulation
- Cancer immunotherapy adjunct
- Antidiabetic
- Wound healing
- Anti-inflammatory
- Antihypertensive
Hot-water extract captures the primary bioactive SCG beta-glucan. Standardise to beta-glucan content (>30% preferred). Fruiting body contains significantly higher beta-glucan than mycelium cultures. Used in Japan as Hanabiratake hot-water extract in cancer support protocols.
shield Safety
Contraindications — Evidence Basis
Immunosuppressant therapy
High beta-glucan content strongly stimulates innate immunity via TLR4 and Dectin-1 receptors. Use under supervision in transplant recipients or patients on biologics.
Autoimmune disease
Potent immunostimulant; may aggravate autoimmune conditions.
Monitoring Parameters
Monitor during use, especially with prolonged or high-dose therapy.
Blood glucose
Blood pressure
Immune markers
Toxicity
Well tolerated in animal studies up to 1000 mg/kg. No human toxicity reported at standard supplemental doses.
Rare: mild GI discomfort at high doses.
Reduce dose if GI intolerance occurs.
Adverse Effects
CYP Metabolism
No CYP450 interactions documented. Beta-glucan is poorly absorbed systemically; acts primarily via gut-associated lymphoid tissue receptors.
swap_horiz Interactions
Immunosuppressants (Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil)
Class: Immunosuppressant
S. crispa beta-glucan (SCG) stimulates splenocytes to produce cytokines including GM-CSF, IFN-gamma, and TNF-alpha via Dectin-1, TLR2, TLR4, and TLR6 receptor activation, potently stimulating innate immune responses. These immunostimulatory effects may reduce the efficacy of immunosuppressive therapy in transplant recipients or patients with autoimmune conditions.
Avoid co-administration in organ transplant recipients on immunosuppressive therapy. Monitor immunosuppressant drug trough levels if Sparassis crispa supplementation is identified. Consult transplant specialist before any supplementation.
Chemotherapy Agents (Cyclophosphamide, Mitomycin C, Cisplatin, 5-Fluorouracil)
Class: Antineoplastic
SCG (S. crispa beta-glucan) modulates hematopoietic response in cyclophosphamide-induced leukopenic mice, restoring white blood cell and platelet counts. Beta-1,3-D-glucan from S. crispa demonstrates anti-angiogenic and anti-metastatic effects, potentially enhancing chemotherapy outcomes. Clinically, S. crispa has been used as adjuvant cancer support in Japan.
This combination may be beneficial as adjuvant support during chemotherapy to mitigate myelosuppression. However, coordinate administration with the oncology team to avoid immunological interference during chemotherapy cycles. Monitor CBC regularly.
Antidiabetic Agents (Metformin, Insulin, Sulfonylureas, Glipizide)
Class: Antidiabetic
S. crispa has documented anti-diabetic properties through beta-glucan modulation of glucose homeostasis, as established in systematic reviews. Beta-glucans reduce postprandial glucose levels by slowing carbohydrate digestion and absorption. Concurrent use with antidiabetic agents may produce additive blood glucose lowering.
Monitor blood glucose levels when initiating S. crispa supplementation alongside antidiabetic medications. Risk of hypoglycaemia is low but present, particularly with insulin or sulfonylureas. Adjust doses as needed.
Antihypertensive Agents (ACE Inhibitors, Calcium Channel Blockers, ARBs, Beta-Blockers)
Class: Antihypertensive
S. crispa has documented anti-hypertensive properties through beta-glucan-mediated mechanisms and eNOS pathway activation in stroke-prone spontaneously hypertensive rat models. Concurrent use with antihypertensive medications may produce additive blood pressure reduction.
Monitor blood pressure regularly in patients combining S. crispa with antihypertensive medications. Adjust antihypertensive doses if symptomatic hypotension occurs. This is generally a low-risk interaction.
Anticoagulants and Antiplatelet Agents (Warfarin, Aspirin, Clopidogrel, Heparin)
Class: Anticoagulant / Antiplatelet
Beta-glucan polysaccharides from S. crispa have immune-activating and vascular effects that may affect platelet function and coagulation cascade. While direct antiplatelet effects are not specifically documented for S. crispa, the cardiovascular-protective properties and immune activation raise theoretical concern for additive bleeding risk when combined with anticoagulants.
Theoretical concern; monitor for unusual bruising or bleeding. Advise discontinuation at least 1 week before elective surgery. No specific dose adjustments needed at standard supplemental doses.
hub Combinations
Synergistic pairings can enhance therapeutic outcomes, while knowing suitable substitutes helps when specific herbs are unavailable or contraindicated.
No combination data available yet.
science Studies
Promising Potential of Crude Polysaccharides from Sparassis crispa against Colon Cancer: An In Vitro Study
In VitroThis in vitro study examined the anticancer, anti-inflammatory, and antioxidant properties of crude polysaccharides isolated from Sparassis crispa (CPS) against human colon cancer cell lines. CPS was non-toxic to normal colon epithelial cells (CCD841 CoN) while simultaneously exhibiting significant antiproliferative effects against colon adenocarcinoma lines (Caco-2, LS180, HT-29). CPS also inhibited pro-inflammatory enzymes cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and lipoxygenase (LOX), indicating dual anticancer and anti-inflammatory mechanisms. Chemical characterization showed CPS is predominantly a carbohydrate-rich extract. Antioxidant activity was moderate by multiple assays. These results support S. crispa polysaccharides as promising chemopreventive and potentially therapeutic candidates for colon cancer.
Induction of dendritic cell maturation by beta-glucan isolated from Sparassis crispa
In VitroThis in vitro study investigated the immunostimulatory mechanisms of a high-branched 1,3-beta-D-glucan (sparan) purified from Sparassis crispa on dendritic cell (DC) maturation and function. Sparan treatment significantly elevated the expression of co-stimulatory molecules (CD40, CD80, CD86, MHC-I/II), and enhanced production of key cytokines (IL-12, IL-1β, TNF-α, IFN-α/β). It also promoted T-cell proliferation and IL-2 production in allogenic T-cell cultures, and inhibited DC endocytosis. Mechanistic studies identified toll-like receptor 4 (TLR4) as the membrane receptor mediating sparan-induced DC maturation. These findings demonstrate that S. crispa beta-glucan is a potent TLR4 agonist with direct immune activation potential, relevant to its antitumor immunomodulatory activities.
medication Dosing
hot_water_extract
1–3 g/day of fruiting body hot-water extract standardised to ≥30% beta-glucan
1–2x/day
Fruiting body extract required for maximum SCG beta-glucan. Mycelium has significantly lower beta-glucan. Used in Japanese integrative oncology at 1 g/day as adjunct. Animal wound-healing studies used 1000 mg/kg equivalent.
Disclaimer: This information is largely AI-generated and reviewed by human experts at Evara Health. It is intended for educational and clinical reference purposes only and should not replace professional medical advice.
© 2026 Evara Health. All rights reserved.